Recent Updates
Recently added Catalysts

NgG low dose investigational vaccine

Phase 1

Sexually Transmitted Diseases | Monoclonal antibody | Other |GSK plc|Last Updated: Aug 7, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment1,004
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05630859Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.PHASE1 COMPLETED 1,004Nov 28, 2022May 22, 2025Aug 7, 202523 United States, Brazil +6
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of participants reporting solicited administration site events in study Phase 1 (Dose-escalation safety lead-in)
During the 7 days follow-up period after the first dose

The solicited administration site events after vaccination include pain, redness, and swelling.

Percentage of participants reporting each solicited systemic event in study Phase 1 (Dose-escalation safety lead-in)
During the 7 days follow-up period after the first dose

The solicited systemic events after vaccination include fever, headache, myalgia, arthralgia, fatigue. Fever is defined as temperature ≥38.0°C/100.4°F. The preferred location for measuring temperature in this study is the oral cavity.

Percentage of participants reporting unsolicited adverse events (AEs) in study Phase 1 (Dose-escalation safety lead-in)
During the 30 days follow-up period after the first dose

Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

Percentage of participants reporting unsolicited AEs in study Phase 1 (Dose-escalation safety lead-in)
During the 30 days follow-up period after the second dose

Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

Percentage of participants reporting serious adverse events (SAEs) in study Phase 1 (Dose-escalation safety lead-in)
From Day 1 after the first dose up to study Phase I end (Day 241)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in an abnormal pregnancy outcome.

Percentage of participants reporting AEs leading to withdrawal in study Phase 1 (Dose-escalation safety lead-in)
From Day 1 after the first dose up to study Phase I end (Day 241)

An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention.

Percentage of participants with haematological and biochemical laboratory abnormalities in study Phase 1 (Dose-escalation safety lead-in)
7 days after the first dose

Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Incidence rates of confirmed gonorrhea cases in study Phase 2 [Efficacy Proof of Concept (PoC)]
From 1 month to 13 months post-Dose 2
Percentage of participants reporting solicited administration site events in study Phase 2 (Efficacy PoC)
During the 7 days follow-up period after the first dose

The solicited administration site events after vaccination include pain, redness, and swelling.

Percentage of participants reporting each solicited systemic event in study Phase 2 (Efficacy PoC)
During the 7 days follow-up period after the first dose

The solicited systemic events after vaccination include fever, headache, myalgia, arthralgia, fatigue. Fever is defined as temperature ≥ 38.0°C/100.4°F. The preferred location for measuring temperature in this study is the oral cavity.

Percentage of participants reporting unsolicited AEs in study Phase 2 (Efficacy PoC)
During the 30 days follow-up period after the first dose

Any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

Percentage of participants reporting SAEs in study Phase 2 (Efficacy PoC)
From Day 1 after the first dose up to study end (Day 451)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in an abnormal pregnancy outcome.

Percentage of participants reporting AEs leading to withdrawal in study Phase 2 (Efficacy PoC)
From Day 1 after the first dose up to study end (Day 451)

An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention.

Percentage of participants with haematological and biochemical laboratory abnormalities in study Phase 2 (Efficacy PoC)
7 days after the first dose

Clinically significant abnormal laboratory findings are those which are not associated with an underlying disease, unless judged by the investigator to be more severe than expected for the participants condition. The evaluation of the endpoint will be assessed in the subsets for intensive safety monitoring.

Secondary Endpoints
Incidence rates of confirmed gonorrhea cases with and without co-infection with a different sexually-transmitted disease causing bacterium in study Phase 2 (Efficacy PoC)
From 1 month to 13 months post-Dose 2
Incidence rates of gonorrhea in study Phase 2 (Efficacy PoC)
From 1 month to 13 months post-Dose 2
Incidence rates of other gonococcal infection with positive Ng in study Phase 2 (Efficacy PoC)
From 1 month to 13 months post-Dose 2
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Phase 1:1a Low dose GroupEXPERIMENTALParticipants randomized to the 1a Low dose Group receive 2 doses of NgG low dose investigational vaccine.
Phase 1:1b Placebo GroupPLACEBO_COMPARATORParticipants randomized to the 1b Placebo Group receive 2 doses of placebo.
Phase 1: 2a Medium dose GroupEXPERIMENTALParticipants randomized to the 2a Medium dose Group receive 2 doses of NgG medium dose investigational vaccine.
Phase 1: 2b Placebo GroupPLACEBO_COMPARATORParticipants randomized to the 2b Placebo Group receive 2 doses of placebo.
Phase 1: 3a High dose GroupEXPERIMENTALParticipants randomized to the 3a High dose Group receive 2 doses of NgG high dose investigational vaccine.
Phase 1: 3b Placebo GroupPLACEBO_COMPARATORParticipants randomized to the 3b Placebo Group receive 2 doses of placebo.
Phase 2: 4a HTD GroupEXPERIMENTALParticipants randomized to the 4a highest tolerated dose (HTD) Group receive 2 doses of NgG highest tolerated dose selected from Phase 1.
Phase 2: 4b dose below HTD GroupEXPERIMENTALParticipants randomized to the 4b dose below HTD Group receive 2 doses of NgG dose below the highest tolerated dose selected from Phase 1.
Phase 2: 4c Placebo GroupPLACEBO_COMPARATORParticipants randomized to the 4c Placebo Group receive 2 doses of placebo.
Interventions
NameTypeDescription
NgG low dose investigational vaccineBIOLOGICALTwo doses of NgG low dose investigational vaccine, administered intramuscularly.
NgG medium dose investigational vaccineBIOLOGICALTwo doses of NgG medium dose investigational vaccine, administered intramuscularly.
NgG high dose investigational vaccineBIOLOGICALTwo doses of NgG high dose investigational vaccine, administered intramuscularly.
PlaceboBIOLOGICALTwo doses of placebo, administered intramuscularly.
NgG HTD investigational vaccineBIOLOGICALTwo doses of NgG HTD investigational vaccine, administered intramuscularly.
NgG below HTD investigational vaccineBIOLOGICALTwo doses of NgG below HTD investigational vaccine, administered intramuscularly.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites23

Inclusion Criteria: Inclusion criteria for the dose-escalation safety lead-in part * Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or witnessed/thumb printed informed consent obtained from the participant prior to perfor...

Countries:United StatesBrazilFranceGermanyPhilippinesSouth AfricaSpainUnited Kingdom
Unlock Eligibility Criteria